A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF ORAL MRT-2359 IN PATIENTS WITH MYC-DRIVEN AND OTHER SELECTED SOLID TUMORS INCLUDING LUNG CANCER AND DIFFUSE LARGE B-CELL LYMPHOMA

The purpose of this study is to evaluate the safety and confirm the best dose in humans for an investigational drug called MRT-2359 in subjects with solid tumors and diffuse large B-cell lymphoma. “Investigational” means the study drug has not been approved for the treatment of participants with cancer by the Food and Drug Administration (“FDA”) or any other health/regulatory authority anywhere in the world.MRT-2359 is called a molecular glue degrader or MGD. This MGD can selectively stick to a protein called G1 To S Phase Transition 1 (GSPT1) and cause GSPT1 to breakdown within the cancer cell. The GSPT1 protein is part of an internal cellular process which helps cancer cells to grow rapidly. MRT- 2359 may help decrease the number of cancer cells in your body by targeting and destroying the GSPT1 protein and leading to cancer cell death. This is the first time that MRT-2359 is being given to humans.

Are you Eligible? (Inclusion Criteria)

• 18 years of age or older 2. Have a predicted life expectancy of ≥ 3 months. 3. Have not received prior chemotherapy, definitive radiation, or biological cancer therapy within 21 days before the first dose of study treatment